Posted by pharmrep on September 1, 2002, at 12:08:26
In reply to Re: Lexapro maintenance dose » pharmrep, posted by Anyuser on September 1, 2002, at 0:45:58
> Forest issued two press releases, one on the 15th announcing approval of lexapro for MDD, and a second on the 29th announcing approval of lexapro for maintenance therapy. Why the separate approvals?
The benefits of sustained pharmacological therapy lasting several months or longer are generally agreed to be essential to the long-term treatment of major depressive disorder. Although controlled, not all of the long-term trials of Lexapro have not yet been completed, systematic evaluation of the racemic compound, citalopram, has demonstrated the benefit of maintaining treatment after an initial response in the first 6-8 wks of therapy. The efficacy of citalopram in maintaining an AD response in patients with recurrent depression who had responded and continued to be improved during an initial 22-25 wks of treatment was demonstrated in 1 trial. The subjects were subsequently observed for relapse for an additional period of up to 76 wks....those results took longer to analyse, and therefore a longer period before presented to the FDA...they have now approved/agreed with those findings.
poster:pharmrep
thread:109458
URL: http://www.dr-bob.org/babble/20020829/msgs/118422.html